FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			or Section 30(n) of the investment Company Act of 1940					
1. Name and Address of Reporting Person [*] Voigtlander Christian B.			2. Issuer Name and Ticker or Trading Symbol <u>ICU MEDICAL INC/DE</u> [ICUI]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) 951 CALLE AMANECER		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/06/2023	X Officer (give title Other (specify below) below) Chief Operating Officer				
(Street) SAN CLEMENTE	CA 92673		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

······································												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Stock	03/06/2023		М		8,745	A	\$0.0	22,260	D			
Common Stock	03/06/2023		F		4,604	D	\$161.25	17,656	D			
Common Stock ⁽¹⁾	03/06/2023		М		1,551	A	\$0.0	19,207	D			
Common Stock	03/06/2023		F		816	D	\$161.25	18,391	D			
Common Stock ⁽¹⁾	03/07/2023		М		2,145	A	\$0.0	20,536	D			
Common Stock	03/07/2023		F		1,129	D	\$157.47	19,407	D			
Common Stock ⁽¹⁾	03/08/2023		М		2,209	A	\$0.0	21,616	D			
Common Stock	03/08/2023		F		1,163	D	\$156.17	20,453	D			

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		on of		6. Date Exerci: Expiration Dat (Month/Day/Ye	e	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Common Stock ⁽¹⁾	\$0.0 ⁽²⁾	03/06/2023		м			1,551	03/06/2023 ⁽²⁾	03/06/2023 ⁽³⁾	Common Stock	1,551	\$ <mark>0.0</mark>	0	D	
Common Stock ⁽¹⁾	\$0.0 ⁽²⁾	03/08/2023		м			2,209	03/08/2023 ⁽⁴⁾	03/08/2024 ⁽³⁾	Common Stock	2,209	\$0.0	2,210	D	
Common Stock ⁽¹⁾	\$0.0 ⁽²⁾	03/07/2023		М			2,145	03/07/2023 ⁽⁴⁾	03/07/2025 ⁽³⁾	Common Stock	2,145	\$ <mark>0.0</mark>	4,291	D	
Performance Shares ⁽⁵⁾	\$0.0 ⁽⁶⁾	03/06/2023		М			8,745	03/06/2023 ⁽⁷⁾	03/06/2023	Common Stock	8,745	\$0.0	0	D	

Explanation of Responses:

1. These securities are Restricted Stock Units.

2. There is neither a purchase price nor an exercise price for the Restricted Stock Units.

3. These are restricted stock units that fully vest 3 years from the grant date.

4. One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date.

5. These Securities are Performance-based Restricted Stock Units (PRSU).

6. There is neither a purchase price nor an exercise price for the PRSUs.

7. These PRSUs were granted on March 6, 2020 and were subject to the satisfaction of both performance-based and time-based criteria. These PRSUs had a 3-year performance period and cliff-vested on the third anniversary of the grant date.

> By: Paula Darbyshire, Attorneyin-fact For: Christian B. 03/08/2023 <u>Voigtlander</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

** Signature of Reporting Person

Date